scholarly journals Trends in Antidepressants Use in Spain between 2015 and 2018: Analyses from a Population-Based Registry Study with Reference to Driving

2020 ◽  
Vol 13 (4) ◽  
pp. 61 ◽  
Author(s):  
Eduardo Gutiérrez-Abejón ◽  
Francisco Herrera-Gómez ◽  
Paloma Criado-Espegel ◽  
F. Javier Álvarez
Keyword(s):  
Traffic Accidents ◽  
Population Distribution ◽  
Population Based ◽  
Driving Under The Influence ◽  
Registry Study ◽  
Starting Point ◽  
And Gender ◽  
Population Based Registry ◽  
Classification Category ◽  
Chronic Use

Antidepressants are considered driving-impairing medicines (DIM). This is a population-based registry study that shows the trend in the use of antidepressants in Castile and León, Spain, from 2015 to 2018. Data on antidepressant dispensations at pharmacies and the adjusted use of these medicines by the driver population are presented. For the purposes of analysis, population distribution by age and gender has been taken into account, as well as the three Driving Under the Influence of Drugs, alcohol, and medicines (DRUID) categories. Antidepressants were used by 8.56% of the general population and 5.66% of drivers. Antidepressants were used more commonly by females than by males (12.12% vs. 4.87%, χ² = 1325.124, p = 0.001), and users increased as the age increased, even if women who drive used less antidepressants after turning 60 years of age. Chronic use of antidepressants was relevant (8.28%) in the same way as daily use (3.15%). Most of the consumption included SSRIs (4.99%), which are also known as “other antidepressants” (3.71%). Regardless of antidepressants consumed, users took 2.75 ± 1.19 DIMs, which are mainly anxiolytics (58.80%) and opioids (26.43%). Lastly, regarding consumption of antidepressants according to the DRUID classification, category I predominated over categories II and III. Our findings should serve as a starting point for health and traffic authorities to raise awareness of the risk for traffic accidents, especially involving SSRIs.

scholarly journals Use of driving-impairing medicines by a Spanish population: a population-based registry study

BMJ Open ◽  
2017 ◽  
Vol 7 (11) ◽  
pp. e017618 ◽  
Author(s):  
Eduardo Gutierrez-Abejón ◽  
Francisco Herrera-Gómez ◽  
Paloma Criado-Espegel ◽  
F Javier Alvarez
Keyword(s):  
General Population ◽  
Census Data ◽  
Population Based ◽  
Spanish Population ◽  
Registry Study ◽  
Age And Gender ◽  
Patterns Of Use ◽  
And Gender ◽  
Population Based Registry ◽  
Chronic Use

ObjectiveTo assess the use of driving-impairing medicines (DIM) in the general population with special reference to length of use and concomitant use.DesignPopulation-based registry study.SettingThe year 2015 granted medicines consumption data recorded in the Castile and León (Spain) medicine dispensation registry was consulted.ParticipantsMedicines and DIM consumers from a Spanish population (Castile and León: 2.4 million inhabitants).ExposureMedicines and DIM consumption. Patterns of use by age and gender based on the length of use (acute: 1–7 days, subacute: 8–29 days and chronic use: ≥30 days) were of interest. Estimations regarding the distribution of licensed drivers by age and gender were employed to determine the patterns of use of DIM.ResultsDIM were consumed by 34.4% (95% CI 34.3% to 34.5%) of the general population in 2015, more commonly with regularity (chronic use: 22.5% vs acute use: 5.3%) and more frequently by the elderly. On average, 2.3 DIM per person were dispensed, particularly to chronic users (2.8 DIM per person). Age and gender distribution differences were observed between the Castile and León medicine dispensation registry data and the drivers’ license census data. Of all DIM dispensed, 83.8% were in the Anatomical Therapeutic Chemical code group nervous system medicines (N), which were prescribed to 29.2% of the population.ConclusionsThe use of DIM was frequent in the general population. Chronic use was common, but acute and subacute use should also be considered. This finding highlights the need to make patients, health professionals, health providers, medicine regulatory agencies and policy-makers at large aware of the role DIM play in traffic safety.

scholarly journals Trend in the use of topical ocular anti-infectives in a region of Spain between 2015 and 2019: a population-based registry study

2020 ◽  
Vol 33 (6) ◽  
pp. 453-458
Author(s):  
Eduardo Gutiérrez-Abejón ◽  
Francisco Herrera-Gómez ◽  
Ignacio J. Ayestarán-Martínez ◽  
Francisco Javier Álvarez ◽  
Keyword(s):  
Population Distribution ◽  
The Elderly ◽  
Population Based ◽  
European Population ◽  
Registry Study ◽  
Total Consumption ◽  
Age And Gender ◽  
Ocular Drugs ◽  
And Gender ◽  
Population Based Registry

Objectives. This study presents the use and trends of use of topical ocular anti-infectives into a European population in the current decade (2015 to 2019) with an analysis of concomitant use with other ocular drugs, considering distribution by age and gender. Patients and Methods. A population-based registry study was carried out to assess the ocular anti-infectives use from 2015 to 2019. All dispensations of these medicines at pharmacies in the largest region of Spain, Castile and León, was accessed. The number of packages dispensed, the percentage of the population under treatment, diagnosis, and the concomitant use with other ocular medicines was observed. For all analyses, the population distribution by age and gender was considered. Results. An average of 198,000 packages of topical ocular anti-infectives were dispensed annually to 5.38% of the population, and more commonly for women than for men (5.83% vs. 4.91%). Children and the elderly used more these medicines. Tobramycin, alone or in combination, accounted for more than 68% of the total consumption (135,000 packages per year), and was the most widely used anti-infective in almost all identified diagnoses. Conjunctivitis (50.12%), and stye (11.51%) were the most frequent diagnoses. The consumption of ocular anti-infectives increased by 8.23% from 2015 to 2019, and more among men than in women. Conclusions. Our findings show that the most used topical ocular anti-infective was tobramycin, in accordance with the clinical practice guidelines recommendations. However, ocular infections are sometimes treated empirically, especially conjunctivitis.

scholarly journals Population-Based Registry Analysis of Antidiabetics Dispensations: Trend Use in Spain between 2015 and 2018 with Reference to Driving

2020 ◽  
Vol 13 (8) ◽  
pp. 165
Author(s):  
Eduardo Gutiérrez-Abejón ◽  
Paloma Criado-Espegel ◽  
Francisco Herrera-Gómez ◽  
F. Javier Álvarez
Keyword(s):  
Population Based ◽  
Driving Under The Influence ◽  
Oral Antidiabetics ◽  
Castilla Y Leon ◽  
Health Authorities ◽  
Minor Influence ◽  
Drivers License ◽  
And Gender ◽  
Population Based Registry ◽  
Registry Analysis

Insulins and some oral antidiabetics are considered to be driving-impairing medicines (DIM) and they belong to the Driving under the Influence of Drugs, alcohol, and medicines (DRUID) category I (minor influence on fitness to drive). The trend of antidiabetics use in Castilla y León from 2015 to 2018 is presented through a population-based registry study. Treatment duration with these medicines and the concomitant use of other DIMs were observed. An adjustment method was used with information from the drivers’ license census. For all calculations, age and gender were taken into account. 3.98% of the general population used at least one antidiabetic, as well as 2.92% of drivers. The consumption of antidiabetics in men was higher than in women (4.35% vs. 3.61%, p = 0.001), and the use increases with age, especially from 35–39 years to 75–79 years in men and 85–89 years in women. Antidiabetics were consumed chronically, specifically 100% in the case of insulins and 95% in the case of oral antidiabetics. In addition to antidiabetics, 2.5 ± 1.86 DIMs were consumed, mainly anxiolytics (25.53%), opioids (23.03%), other analgesics and antipiretics (19.13%), and antidepressants (17.73%). Collaboration between pharmacists and physicians is a priority to clearly transmitting risks to patients. It is necessary that the health authorities include information on DIMs, such as the DRUID classification, in the prescription and dispensing software.

Neonatal and maternal outcome after blastocyst transfer: a population-based registry study

2016 ◽  
Vol 214 (3) ◽  
pp. 378.e1-378.e10 ◽  
Author(s):  
Erica Ginström Ernstad ◽  
Christina Bergh ◽  
Ali Khatibi ◽  
Karin B.M. Källén ◽  
Göran Westlander ◽  
...  
Keyword(s):  
Population Based ◽  
Maternal Outcome ◽  
Blastocyst Transfer ◽  
Registry Study ◽  
Population Based Registry

scholarly journals The burden and costs of prevention and management of genital disease caused by HPV in women: A population-based registry study in Finland

2013 ◽  
Vol 133 (6) ◽  
pp. 1459-1469 ◽  
Author(s):  
Heini Salo ◽  
Tuija Leino ◽  
Terhi Kilpi ◽  
Kari Auranen ◽  
Petri Tiihonen ◽  
...  
Keyword(s):  
Population Based ◽  
Registry Study ◽  
Population Based Registry ◽  
Genital Disease

Riluzole and other prognostic factors in ALS: a population-based registry study in Italy

2018 ◽  
Vol 265 (4) ◽  
pp. 817-827 ◽  
Author(s):  
Jessica Mandrioli ◽  
◽  
Sara Angela Malerba ◽  
Ettore Beghi ◽  
Nicola Fini ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Population Based ◽  
Registry Study ◽  
Population Based Registry

scholarly journals Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Julio García-Suárez ◽  
◽  
Javier de la Cruz ◽  
Ángel Cedillo ◽  
Pilar Llamas ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Cancer Therapy ◽  
Hematologic Malignancy ◽  
Large Population ◽  
Hematologic Malignancies ◽  
Population Based ◽  
Clinical Severity ◽  
Primary Study ◽  
Registry Study ◽  
Population Based Registry

Abstract Background Patients with cancer have been shown to have a higher risk of clinical severity and mortality compared to non-cancer patients with COVID-19. Patients with hematologic malignancies typically are known to have higher levels of immunosuppression and may develop more severe respiratory viral infections than patients with solid tumors. Data on COVID-19 in patients with hematologic malignancies are limited. Here we characterize disease severity and mortality and evaluate potential prognostic factors for mortality. Methods In this population-based registry study, we collected de-identified data on clinical characteristics, treatment and outcomes in adult patients with hematologic malignancies and confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection within the Madrid region of Spain. Our case series included all patients admitted to 22 regional health service hospitals and 5 private healthcare centers between February 28 and May 25, 2020. The primary study outcome was all-cause mortality. We assessed the association between mortality and potential prognostic factors using Cox regression analyses adjusted for age, sex, comorbidities, hematologic malignancy and recent active cancer therapy. Results Of 833 patients reported, 697 were included in the analyses. Median age was 72 years (IQR 60–79), 413 (60%) patients were male and 479 (69%) and 218 (31%) had lymphoid and myeloid malignancies, respectively. Clinical severity of COVID-19 was severe/critical in 429 (62%) patients. At data cutoff, 230 (33%) patients had died. Age ≥ 60 years (hazard ratios 3.17–10.1 vs < 50 years), > 2 comorbidities (1.41 vs ≤ 2), acute myeloid leukemia (2.22 vs non-Hodgkin lymphoma) and active antineoplastic treatment with monoclonal antibodies (2·02) were associated with increased mortality; conventional chemotherapy showed borderline significance (1.50 vs no active therapy). Conversely, Ph-negative myeloproliferative neoplasms (0.33) and active treatment with hypomethylating agents (0.47) were associated with lower mortality. Overall, 574 (82%) patients received antiviral therapy. Mortality with severe/critical COVID-19 was higher with no therapy vs any antiviral combination therapy (2.20). Conclusions In this series of patients with hematologic malignancies and COVID-19, mortality was associated with higher age, more comorbidities, type of hematological malignancy and type of antineoplastic therapy. Further studies and long-term follow-up are required to validate these criteria for risk stratification.

Sign in / Sign up

Export Citation Format

Share Document